Skip to search formSkip to main contentSkip to account menu

PLX4032

Known as: B-Raf inhibitor PLX4032, PLX 4032, PLX-4032 
National Institutes of Health

Related topics

Related topics

2 relations
RG7204

Broader (1)

Vemurafenib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells
Background and AimsThe activating mutation BRAFV600E is a frequent genetic event in papillary thyroid carcinomas (PTC). Mutation… 
2016
2016
Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM
A large proportion of melanomas harbour the activating BRAFV600E mutation that renders these cells dependent on MAPK signalling… 
Highly Cited
2015
Highly Cited
2015
Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells.
Highly Cited
2014
Highly Cited
2014
Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAFV600E inhibition and can be targeted to reduce resistance
Tumor angiogenesis is essential for tumor growth and metastasis and is dependent on key angiogenic factors. Angiogenin (ANG), a… 
2013
2013
Skin tumorigenesis stimulated by Raf inhibitors relies upon Raf functions that are dependent and independent of ERK.
RAF inhibitors achieve unprecedented but mainly transient clinical responses in patients with melanoma whose tumors harbor an… 
2011
2011
RNA interference of pheromone biosynthesis-activating neuropeptide receptor suppresses mating behavior by inhibiting sex pheromone production in Plutella xylostella (L.).
2011
2011
PLX4032 and melanoma: resistance, expectations and uncertainty
Last year, the results of a Phase I/II study demonstrated an 80% response rate to PLX4032 (Plexxikon; RG7204, Roche… 
2011
2011
Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling.
RAS mutations occur in more than 30% of all human cancers but efforts to directly target mutant RAS signaling as a cancer therapy… 
Review
2011
Review
2011
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.
Papillary thyroid cancer (PTC) rates continue to increase in the United States and Europe, and, although most patients do well… 
Highly Cited
1992
Highly Cited
1992
The Effect of Continuous Interscalene Brachial Plexus Block with 0.125% Bupivacaine Plus Fentanyl on Diaphragmatic Motility and Ventilatory Function
Background and Objectives. Continuous interscalene brachial plexus block with 0.25% bupivacaine decreases diaphragmatic motility… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)